Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.
Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.
FDA Approves Anixa Biosciences' Ovarian Cancer CAR-T Therapy for Individual Patient Trial. Moffit Cancer Center receives approval for a second dose in an ongoing Phase I trial showing early promising results.
Anixa Biosciences (NASDAQ: ANIX) is an interesting, undiscovered biotech company that seeks to disrupt the cancer landscape by working with some highly credible partners. The company is undiscovered for many reasons including its history.
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the human immune system has led to the development of innovative immuno-therapy drugs that have been approved and commercialized.
The Dow Jones edged higher on Friday, recording gains for the tenth straight session. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
